Following 6.3% Q1 Sales Slump, Herbalife Expects To Ride North America To Turnaround
Executive Summary
Direct seller declines to provide guidance due to dynamic macroeconomic environment but expects a return to growth by end of year led by North America.
You may also be interested in...
US Q2 Consumer Health Earnings Preview: Two Firsts On Table For Perrigo, One For Kenvue
Perrigo will note regulatory approval for Opill as first US OTC oral contraceptive in first earnings briefing with Patrick Lockwood-Taylor at helm. Other firsts in sector will be Kenvue’s 20 July results being its first since spin-out from J&J in May and Bausch + Lomb’s first quarterly results under CEO Saunders.
Herbalife Relaunches To ‘2.0’ With 'Unified, Global Platform' After Sales Fall 10.3% In 2022
Direct seller announces relaunch after year-long sales slump blamed on macroeconomic inflationary pressures. No full-year guidance due to rapidly shifting macroeconomic environment and increased market volatility.
Twice Retired Herbalife CEO Johnson Returns To Helm For $1 Salary Plus Stock Incentives
Michael Johnson previously was CEO from 2003 to 2017 and from 2019 to early 2020, as well as chairman from 2007 to early 2020. Direct seller granted him an equity-based long-term incentive plan in stock appreciation rights and restricted stock units.